{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=25&state=California", "query": { "state": "California", "city": "Sacramento", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 5550, "total_pages": 555, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=26&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=24&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T06:59:30.319Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05684965", "title": "XTX301 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "XTX301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xilio Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2023-05-11", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 12, "location_summary": "Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05684965" }, { "nct_id": "NCT01383265", "title": "Combined Chromoendoscopy and Water Method for Screening Colonoscopy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colon Polyp" ], "interventions": [ { "name": "Water method and chromoendoscopy", "type": "PROCEDURE" }, { "name": "Water method", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "VA Northern California Health Care System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 1177, "start_date": "2010-03", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-06-17", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 1, "location_summary": "Mather, California", "locations": [ { "city": "Mather", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383265" }, { "nct_id": "NCT01049919", "title": "Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Critical Limb Ischemia", "Peripheral Arterial Disease", "Peripheral Vascular Disease" ], "interventions": [ { "name": "Bone marrow concentration device", "type": "DEVICE" }, { "name": "Placebo procedure (sham)", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Zimmer Biomet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 153, "start_date": "2010-06", "completion_date": "2020-02", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01049919" }, { "nct_id": "NCT00677365", "title": "Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis (CF)" ], "interventions": [ { "name": "MP-376", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 151, "start_date": "2008-06", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 39, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00677365" }, { "nct_id": "NCT03178071", "title": "Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non Small Cell Lung Cancer ALK Positive or ROS1 Positive" ], "interventions": [ { "name": "Lorlatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 49, "location_summary": "Sedona, Arizona • Huntington Beach, California • Irvine, California + 30 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03178071" }, { "nct_id": "NCT00077636", "title": "ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1469, "start_date": "2003-12", "completion_date": "2006-03", "has_results": true, "last_update_posted_date": "2016-02-23", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077636" }, { "nct_id": "NCT05996471", "title": "A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH3810109", "type": "BIOLOGICAL" }, { "name": "Cabotegravir", "type": "DRUG" }, { "name": "Standard of care (SOC)", "type": "DRUG" }, { "name": "rHuPH20", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 185, "start_date": "2023-08-17", "completion_date": "2028-11-09", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996471" }, { "nct_id": "NCT01290367", "title": "Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Degenerative Disc Disease" ], "interventions": [ { "name": "Single Dose MPCs Injection", "type": "BIOLOGICAL" }, { "name": "Single injection of saline solution", "type": "PROCEDURE" }, { "name": "Single injection of hyaluronic acid", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mesoblast, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2011-08", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2020-06-26", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01290367" }, { "nct_id": "NCT01979536", "title": "Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Positive", "Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma", "Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma", "Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 137, "start_date": "2013-11-13", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01979536" }, { "nct_id": "NCT02111564", "title": "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure", "Respiratory Insufficiency", "Stroke Acute", "Infectious Diseases", "Rheumatic Diseases" ], "interventions": [ { "name": "Rivaroxaban, 10 mg", "type": "DRUG" }, { "name": "Rivaroxaban, 7.5 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 12024, "start_date": "2014-01-07", "completion_date": "2018-05-03", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-31T06:59:30.319Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02111564" } ] }